Development of Monoclonal Antibody Therapeutics for Anthrax

NIH RePORTER · NIH · N01 · $1,448,422 · view on reporter.nih.gov ↗

Abstract

This contract supports the advanced development of a therapeutic for the treatment of anthrax. The scope of work for this contract includes preclinical and clinical development activities that fall into the following areas: IND-enabling activities; manufacturing activities; animal study activities; and BLA-enabling activities.

Key facts

NIH application ID: 10428336
Project number: 272200800040C-P00005-9999-1
Recipient: EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
Principal Investigator: Virginia G. Johnson
Activity code: N01
Funding institute: NIH
Fiscal year: 2021
Award amount: $1,448,422
Award type: —
Project period: 2008-09-01 → 2012-08-31